Kura Oncology to Present Data on KO-2806 with KRAS G12C and Pan-RAS Inhibitors

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for cancer treatment, is set to present new preclinical data. This data supports the combination of its innovative farnesyl transferase inhibitor (FTI) KO-2806 with targeted therapies, such as KRASG12C inhibitors and pan-RAS inhibitors. The presentation will take place at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

The company’s President and CEO, Troy Wilson, Ph.D., J.D., expressed anticipation about showcasing updates to their preclinical and clinical findings. These findings highlight the potential of KO-2806 to enhance the effectiveness of KRASG12C and pan-RAS inhibitors. This could be crucial in overcoming the resistance often seen with these targeted therapies in cancers driven by KRAS mutations. Such cancers include KRASG12C non-small cell lung cancer (NSCLC) and KRAS-mutant colorectal cancers. If the strategy proves successful, KO-2806 could significantly boost antitumor activity and serve as a combination partner for various targeted therapies in treating solid tumors.

The detailed session information for the presentation includes:
1. KO-2806 re-sensitizing KRAS G12C NSCLC tumors to specific inhibitors through mTOR signaling inhibition. This session is scheduled for Friday, October 25, 2024, from 9:00 AM to 3:00 PM ET in the Drug Resistance and Modifiers section of the Exhibition Hall, with poster number PB376.
2. KO-2806 sensitizing colorectal cancers to pan-RAS inhibition. This session is also scheduled for Friday, October 25, 2024, from 9:00 AM to 3:00 PM ET in the Drug Resistance and Modifiers section of the Exhibition Hall, with poster number PB378.

KO-2806 is designed to be a next-generation inhibitor of farnesyl transferase, aiming to enhance the potency, pharmacokinetic properties, and other characteristics compared to earlier FTI drug candidates. At a previous conference, Kura presented preclinical data that supports combining KO-2806 with various targeted therapies like tyrosine kinase inhibitors and KRASG12D inhibitors. Currently, KO-2806 is being evaluated in a Phase 1 dose-escalation trial (FIT-001) both as a standalone therapy and in combination with cabozantinib for clear cell renal cell carcinoma and with adagrasib for KRASG12C NSCLC.

Kura Oncology, committed to advancing precision medicines for cancer, has a pipeline comprising small molecule drug candidates targeting cancer signaling pathways. One of their major drug candidates, Ziftomenib, which targets the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation from the U.S. FDA for treating relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML). The company has completed enrollment in a Phase 2 trial for this indication and is also testing Ziftomenib in combination with current standards of care for newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML.

In addition to KO-2806, Kura is also studying Tipifarnib, another selective FTI, in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN).

Kura Oncology continues to advance its clinical programs to bring promising cancer therapies to patients.